Press release
Hutchinson-Gilford Progeria Syndrome Market Driven by Advancements in Gene Therapy and R&D Funding 2025-2033 | Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Ultragenyx Pharmaceutical Inc.
Global Hutchinson-Gilford progeria syndrome market reached US$ 102.1 billion in 2024 and is expected to reach US$ 207.21 billion by 2031, growing at a CAGR of 8.6% during the forecast period 2024-2031.Hutchinson-Gilford Progeria Syndrome Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With a focus on emerging drug technologies, evolving treatment paradigms, and regulatory frameworks, the report delivers strategic insights to support stakeholders in navigating the rapidly advancing sector from 2025 to 2033.
Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/hutchinson-gilford-progeria-syndrome-market?ophp
Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare genetic disorder causing accelerated aging in children, typically linked to a mutation in the LMNA gene. The treatment market is niche but growing due to increased research into gene-targeted therapies, recent FDA approvals, and global advocacy efforts for early diagnosis and trial access.
Hutchinson-Gilford Progeria Syndrome Market Competitors Overview:
Eiger BioPharmaceuticals, Inc., The Progeria Research Foundation, Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Ultragenyx Pharmaceutical Inc.
Important Industry Updates of 2023, 2024 and 2025:
✅ In May 2024, Sentynl Therapeutics acquired Zokinvy® (lonafarnib)-originally developed by Eiger-for up to $26 million, gaining control of the only FDA-approved HGPS therapy
✅ PRG Science & Technology began a Phase 2a trial for its oral candidate Progerinin in October 2024, receiving FDA approval to enroll patients for the study
Methodology and Scope
The Hutchinson-Gilford Progeria Syndrome Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/hutchinson-gilford-progeria-syndrome-market?ophp
Hutchinson-Gilford Progeria Syndrome Market Segments Overview:
∎ By Treatment Type (Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)), Low-Dose Aspirin, Physical and Occupational Therapy, Hearing Aids, Genetic Counseling, Others)
∎ By End-User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others)
Regional Overview for Hutchinson-Gilford Progeria Syndrome Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=hutchinson-gilford-progeria-syndrome-market?ophp
The Report Covers:
➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.
People Also Ask:
➤ What are the current global trends in sales, production, imports, and exports within the «Keyword» market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the «Keyword» market?
Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hutchinson-Gilford Progeria Syndrome Market Driven by Advancements in Gene Therapy and R&D Funding 2025-2033 | Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Ultragenyx Pharmaceutical Inc. here
News-ID: 4108316 • Views: …
More Releases from DataM intelligence 4 Market Research LLP

Contact Probe Market to 2035: DataM Intelligence Forecasts Steady Growth Driven …
The global Contact Probe Market is projected to expand from USD 1.45 billion in 2024 to USD 2.35 billion by 2033, at a CAGR of 5.5%. Growth is fueled by rising demand for semiconductor testing, miniaturization of electronic components, and the rapid expansion of 5G, automotive electronics, and consumer devices. According to DataM Intelligence, the United States and Asia (especially Japan and South Korea) are the primary innovation hubs for…

Asia-Pacific Spatial Computing Market 2025 | Rising Demand, Growth Drivers & Inv …
Market Size and Growth
Asia-Pacific Spatial Computing Market reached US$ 44.77 billion in 2024 and is expected to reach US$ 302.58 billion by 2032, growing with a CAGR of 27.5% during the forecast period 2025-2032.
Key Development:
Asia-Pacific Spatial Computing: Recent Developments
✅ United States: Industry Developments
✅ In July 2025, Arm announced a $250 million partnership with Malaysia to develop AI chips locally, marking its first such agreement with a country.
✅ In June…

United States Eye Tracking in Healthcare Market 2025 | Growth Drivers & Investme …
Market Size and Growth
The global eye tracking in healthcare market reached US$ 802.87 million in 2024 and is expected to reach US$ 5,155.83 million by 2033, growing at a CAGR of 21.4 % during the forecast period of 2025-2033.
Key Development:
United States: Recent Industry Developments
✅ In September 2025, Optain Health secured $26 million in Series A funding to expand its AI-driven retinal imaging technology, Oculomics, enhancing early diagnosis of eye diseases…

Latin America Pain Management Drugs Market 2025 | Growth Drivers, Market Expansi …
Market Size and Growth
The Latin America pain management drugs market reached US$ 4,069.52 million in 2024 and is expected to reach US$ 6,576.78 million by 2033, growing at a CAGR of 5.6% during the forecast period 2025-2033.
Key Development:
Latin America: Recent Developments in Pain Management Drugs
✅ In January 2025, SteinCares announced a commercialization agreement with Molteni Farmaceutici to expand access to Oramorph®, a novel morphine oral solution, in Ecuador, Brazil…
More Releases for Progeria
Hutchinson-Gilford Progeria Syndrome Market Trends Point to Steady Growth Ahead, …
DelveInsight's "Hutchinson-Gilford Progeria Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Hutchinson-Gilford Progeria Syndrome, historical and forecasted epidemiology as well as the Hutchinson-Gilford Progeria Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report delivers a detailed analysis of Hutchinson-Gilford Progeria Syndrome, covering revenue patterns, prevalence, and the treatment landscape. It provides…
Hutchinson-Gilford Progeria Syndrome Market Expected to Reach Rapid Growth by 20 …
Global Hutchinson-Gilford progeria syndrome market reached to reach at a significant CAGR during the forecast period 2024-2031.
Hutchinson-Gilford Progeria Syndrome Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive…
Hutchinson-Gilford Progeria Treatment Market Outlook, and Opportunity Analysis, …
Hutchinson-Gilford progeria syndrome is a genetic condition characterized by the dramatic, rapid, appearance of aging from the childhood. Hutchinson-Gilford progeria syndrome is caused by a mutation in the lamin A (LMNA) gene. The affected children develop a characteristic facial experience including prominent eyes, small chin, protruding ears, thin lips and a thin nose with a beaked tip. This syndrome also causes hair loss (alopecia), joint abnormalities, aged-looking skin, and a…
Hutchinson-Gilford Progeria Treatment Market - Global Industry Insights, Trends, …
Hutchinson-Gilford progeria is a rare condition that affects about one in four million newborns worldwide according to the National Institutes of Health (NIH). Until now more than 130 cases have been reported as per the NIH statistics. The affected patients live up to 30 years maximum, with an average life span of 13 years. Nearly 90% of the patients die from complications related to atherosclerosis. Till 2012 there wasn’t any…
Hutchinson-Gilford Progeria Treatment Market, Company Analysis and Forecast to 2 …
Hutchinson-Gilford progeria syndrome is a genetic condition characterized by the dramatic, rapid, appearance of aging from the childhood. Hutchinson-Gilford progeria syndrome is caused by a mutation in the lamin A (LMNA) gene. The affected children develop a characteristic facial experience including prominent eyes, small chin, protruding ears, thin lips and a thin nose with a beaked tip. This syndrome also causes hair loss (alopecia), joint abnormalities, aged-looking skin, and a…
Hutchinson-Gilford Progeria Treatment Market - Trends, Outlook, and Opportunity …
Hutchinson-Gilford progeria syndrome is a genetic condition characterized by the dramatic, rapid, appearance of aging from the childhood. Hutchinson-Gilford progeria syndrome is caused by a mutation in the lamin A (LMNA) gene. The affected children develop a characteristic facial experience including prominent eyes, small chin, protruding ears, thin lips and a thin nose with a beaked tip. This syndrome also causes hair loss (alopecia), joint abnormalities, aged-looking skin, and a…